Aug

28

FDA Grants Fast Track Designation For Oncogenex Pharmaceuticals’ Lead Product Candidate OGX-011

≡ Category: Cancer, Cancer Lawsuits, Medical News, Mesothelioma Info | ≅ Leave a Comment

(Mesothelioma News) BOTHELL, WA and VANCOUVER — OncoGenex Pharmaceuticals announced today that OGX-011, also known as custirsen sodium, received Fast Track designation from the U.S. Food & Drug Administration (FDA) in combination with docetaxel for progressive metastatic prostate cancer. OGX-011 is currently completing five Phase 2 clinical studies in prostate, lung and breast cancer, and [...]

Aug

27

Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors

≡ Category: Drugs & RX, Medical News, Vioxx Lawsuit | ≅ Leave a Comment

DRUGS & RX: INDIANAPOLIS, August 26, 2008 /PRNewswire/ — Semafore Pharmaceuticals Inc. presented data at the Seventh International Congress on Targeted Therapies in Cancer in Washington, D.C., announcing the discovery of novel multi-targeted kinase inhibitors…

View the source of this article…

Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors was another wonderful and informative drug and pharmaceutical article [...]

Aug

27

SF1126, Semafore’s PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines

≡ Category: Drugs & RX, Medical News, Vioxx Lawsuit | ≅ Leave a Comment

DRUGS & RX: INDIANAPOLIS, August 26, 2008 /PRNewswire/ — Semafore Pharmaceuticals Inc. announced data presented at the Seventh International Congress on Targeted Therapies in Cancer in Washington, D.C., showing additional antiangiogenic activity of…

View the source of this article…

SF1126, Semafore’s PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell [...]

Aug

27

Professor John F. Thompson to Present at Perspectives in Melanoma XII, Thursday October 2, 2008

≡ Category: Drugs & RX, Medical News, Vioxx Lawsuit | ≅ Leave a Comment

DRUGS & RX: KNOXVILLE, Tenn.–(BUSINESS WIRE)–Aug 26, 2008 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that the Lead Investigator for its phase 2 melanoma study,…

View the source of this article…

Professor John F. Thompson to Present at Perspectives in Melanoma XII, Thursday October 2, 2008 was another [...]

Aug

27

Synta Announces Publication of Elesclomol Mechanism of Action Results in AACR Journal Molecular Cancer Therapeutics

≡ Category: Drugs & RX, Medical News, Vioxx Lawsuit | ≅ Leave a Comment

DRUGS & RX: LEXINGTON, Mass.–(BUSINESS WIRE)–Aug 22, 2008 - Synta Pharmaceuticals Corp., (NASDAQ: SNTA) today announced the publication of new findings in the American Association for Cancer Research journal, Molecular Cancer Therapeutics that describe the…

View the source of this article…

Synta Announces Publication of Elesclomol Mechanism of Action Results in AACR Journal Molecular Cancer Therapeutics was [...]

Aug

27

Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject at the 12th World Congress on Pain

≡ Category: Drugs & RX, Medical News, Vioxx Lawsuit | ≅ Leave a Comment

DRUGS & RX: GLASGOW, Scotland–(BUSINESS WIRE)–Aug. 21, 2008 - Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of novel products for pain management, today presented new and successful secondary endpoint data from a previously announced pivotal…

View the source of this article…

Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject at the 12th World [...]

Aug

27

Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for Byetta

≡ Category: Drugs & RX, Medical News, Vioxx Lawsuit | ≅ Leave a Comment

DRUGS & RX: SAN DIEGO and INDIANAPOLIS, August 26, 2008 /PRNewswire-FirstCall/ — Amylin Pharmaceuticals, Inc. and Eli Lilly and Company in a conference call today provided context and additional information regarding the August 18, 2008 U.S. Food and Drug…

View the source of this article…

Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for Byetta [...]

Aug

27

Noven Provides Update on Daytrana Methylphenidate Transdermal System

≡ Category: Drugs & RX, Medical News, Vioxx Lawsuit | ≅ Leave a Comment

DRUGS & RX: MIAMI–(BUSINESS WIRE)–Aug 25, 2008 - Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today provided an update on the status of Daytrana(R), the only transdermal patch indicated for the treatment of the symptoms of Attention Deficit Hyperactivity…

View the source of this article…

Noven Provides Update on Daytrana Methylphenidate Transdermal System was another wonderful and informative drug and [...]

Aug

24

Ariad Begins Phase 2 Clinical Trial Of Oral Deforolimus In Patients With Metastatic Breast Cancer

≡ Category: Cancer, Cancer Lawsuits, Doctors, Drugs & RX, Hospitals, Medical News, Mesothelioma Info, Uncategorized, Vioxx Lawsuit | ≅ Leave a Comment

MEDICAL NEWS: Ariad Pharmaceuticals announced that it has initiated a Phase 2 clinical trial to examine the efficacy and safety of oral deforolimus, its investigational mTOR inhibitor, in patients with advanced breast (boob) cancer. In a release the CompaNY (New York) noted the following: In collaboration with Merck & Co., deforolimus is currently being [...]

Aug

23

Pain Therapeutics and King Pharmaceuticals Announce Final Data of Remoxy Phase III Study at World Pain Congress in Scotland

≡ Category: Drugs & RX, Medical News, Vioxx Lawsuit | ≅ Leave a Comment

DRUGS & RX: GLASGOW, SCOTLAND - August 19, 2008 - Pain Therapeutics, Inc. (NASDAQ: PTIE) and King Pharmaceuticals, Inc. (NYSE: KG) today presented the final data set of a previously announced pivotal Phase III study of REMOXY, an…

View the source of this article…

Pain Therapeutics and King Pharmaceuticals Announce Final Data of Remoxy Phase III Study [...]

Aug

23

Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors

≡ Category: Drugs & RX, Medical News, Vioxx Lawsuit | ≅ Leave a Comment

DRUGS & RX: CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)–Aug 19, 2008 - Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and…

View the source of this article…

Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors [...]

Aug

23

Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration

≡ Category: Drugs & RX, Medical News, Vioxx Lawsuit | ≅ Leave a Comment

DRUGS & RX: TARRYTOWN, N.Y. & LEVERKUSEN, Germany–(BUSINESS WIRE)–Aug 19, 2008 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG today announced that patients with wet age-related macular degeneration (AMD) receiving VEGF Trap-Eye…

View the source of this article…

Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a [...]

keep looking »